Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
By Timothy R. Rebbeck, T. Friebel, H. Lynch, S. Neuhausen, Laura van ’t Veer, J. Garber, G. Evans, S. Narod, C. Isaacs, E. Matloff and 3 more. Journal of Clinical Oncology, 2004
1,067 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics, Oncology
View Paper: https://www.semanticscholar.org/paper/212cfe87b025c308a4dfa46ba654d7e3741da37b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
Citations in the corpus
- Feelings and Consumer Decision Making: Extending the Appraisal-Tendency Framework (2007, background): “For example, some women choose to have preventative doublemastectomies or preventative oophorectomies, based on their risk for developing breast cancer (Rebbeck et al., 2004).”
- Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. (2005, background): “BRCA1 and BRCA2 mutation carriers benefit from prophylactic strategies including bilateral oophorectomy [10, 11], bilateral mastectomy with reconstruction [12] and chemoprevention, while the role of intensified surveillance is controversial [13].”
- Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. (2005, background): “BRCA2 mutations compared with so-called watchful waiting.(13-16) Nonetheless, the perceived mutilating effects of mastectomy make the decision for surgical prevention difficult, and current national guidelines do not recommend it as standard management.”
- Awareness and current knowledge of breast cancer (2017, background): “Bilateral prophylactic mastectomy decreases the chances of development of breast cancer but does not eliminate the risk of developing cancer completely [169].”
- Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. (2007, background): “Carriers of mutations of BRCA1 and BRCA2 were investigated for the effects of bilateral prophylactic salpingo-oophorectomy (BPSO) [9] or for bilateral or contralateral mastectomy [10] for reduction of the risk of breast and ovarian cancer.”
- BRCA1 and BRCA2: 1994 and beyond (2004, background): “There is now compelling evidence that both preventive mastectomy and preventive oophorectomy can markedly reduce cancer ris”